Nevertheless, a more specific analysis should be performed, also considering that an association with a worse outcome was observed in patients treated at relapse with venetoclax and the monoclonal antibody (MoAb) rituximab in patients carrying Notch1 mutations that are present at high frequency in trisomy 12 CLL cases (37). Here, NOTCH1 is linked to B-cell chronic lymphocytic leukemia.